- Home
- CSGS vs SUPN Comparison
CSGS vs SUPN Comparison
Compare CSGS & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSGS
- SUPN
- Stock Information
- Founded
- CSGS 1994
- SUPN 2005
- Country
- CSGS United States
- SUPN United States
- Employees
- CSGS N/A
- SUPN N/A
- Industry
- CSGS EDP Services
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- CSGS Technology
- SUPN Health Care
- Exchange
- CSGS Nasdaq
- SUPN Nasdaq
- Market Cap
- CSGS 1.9B
- SUPN 1.8B
- IPO Year
- CSGS 1996
- SUPN 2012
- Fundamental
- Price
- CSGS $61.85
- SUPN $33.18
- Analyst Decision
- CSGS Buy
- SUPN Hold
- Analyst Count
- CSGS 8
- SUPN 2
- Target Price
- CSGS $68.29
- SUPN $36.00
- AVG Volume (30 Days)
- CSGS 203.8K
- SUPN 760.7K
- Earning Date
- CSGS 08-06-2025
- SUPN 08-05-2025
- Dividend Yield
- CSGS 2.01%
- SUPN N/A
- EPS Growth
- CSGS 33.32
- SUPN N/A
- EPS
- CSGS 2.92
- SUPN 1.11
- Revenue
- CSGS $1,201,566,000.00
- SUPN $667,997,000.00
- Revenue This Year
- CSGS $4.49
- SUPN N/A
- Revenue Next Year
- CSGS $3.92
- SUPN $12.02
- P/E Ratio
- CSGS $21.16
- SUPN $29.92
- Revenue Growth
- CSGS 3.08
- SUPN 11.82
- 52 Week Low
- CSGS $40.89
- SUPN $27.05
- 52 Week High
- CSGS $67.60
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- CSGS 37.76
- SUPN 60.49
- Support Level
- CSGS $63.71
- SUPN $31.35
- Resistance Level
- CSGS $66.99
- SUPN $33.80
- Average True Range (ATR)
- CSGS 1.43
- SUPN 0.92
- MACD
- CSGS -0.25
- SUPN 0.16
- Stochastic Oscillator
- CSGS 3.02
- SUPN 79.12
About CSGS CSG Systems International Inc.
CSG Systems International Inc is a purpose-driven, SaaS platform company that enables companies in a wide variety of industry verticals to tackle the growing complexity of business in the digital age. The company's cloud-first architecture and customer-centric approach empower companies to deliver unforgettable experiences for B2B (business-to-business), B2C (business-to-consumer), and B2B2X (business-to-business-to-consumer) customers, making it easier for people and businesses to connect to, use and pay for the services the company offers. The company operates in one segment i.e. Solutions and Services. Geographically, the company generates revenue from the United States.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.